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THE PROPERTIES of a clinically useful
radiosensitizer of hypoxic and therefore
radioresistant cells of solid tumours have
been listed (Emmerson and Howard-
Flanders, 1965; Adams, 1973). Many of
these criteria have been met in different
drugs and recent progress has centred
around a number of nitro-heterocyclic
compounds (Chapman et al., 1972; Foster
and Willson, 1973; Asquith et al., 1974b).
The nitro-heterocyclic drug metroni-
dazole (Flagyl, May and Baker) has been
shown to increase the radiosensitivity of
solid murine tumours (Begg, Sheldon and
Foster, 1974; Rauth and Kaufman, 1975;
Stone and Withers, 1974) and possesses
favourable pharmacological and toxico-
logical properties (see Asquith et al.,
1974a for references) which have enabled
the high drug doses required (about
200 mg/kg body weight) to be used in
conjunction with radiotherapy in man
(Urtasun et al., 1974; Deutsch et al.,
1975).
Metronidazole is a 5-nitroimidazole
and there are theoretical reasons for
expecting the analogous 2-nitroimidazoles
to be more efficient radiosensitizers
(Asquith et al., 1974b). Ro-07-0582 (1-(2-
nitro-1-imidazolyl)-3-methoxy-2-propanol,
Roche Products Ltd) was selected for
in vivo work on the basis of the results
of in vitro testing of a number of 2-nitro-
imidazole compounds.
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In various murine tumours given single
doses of x-rays enhancement ratios of
1*0-1*8 have been obtained using Ro-07-
0582 in doses of 0-2-0-3 mg/g body weight
(Rauth and Kaufman, 1974; Begg et al.,
unpublished results) showing higher en-
hancement ratios than metronidazole at
a given drug dose. From serum concen-
tration measurements in mice given doses
of Ro-07-0582 it was concluded that
a peak concentration of at least 100
,ug/ml would have to be achieved in
man for detectable sensitization to be
anticipated, which is greater than that
expected from doses of metronidazole
known to be tolerated as multiple doses
in man (Foster and Flockhart, to be
published). Extrapolation from the
murine data on a weight for weight basis
suggested a dosage of 12 g for a 70 kg
subject whilst data from serum concen-
tration measurements in man after rela-
tively small doses of Ro-07-0582 (de Silva,
Munno and Strojny, 1970) suggested that
between 6-5 and 13-0 g would produce a
serum concentration of 100 ,ug/ml. To
clarify this position, doses of between 25
and 150 mg/kg body weight were given to
dogs and serum concentration measured
as a function of time (Foster and Flock-
hart, to be published). From these
results a dose of about 6 g was estimated
to be required to reach 100 ,ug/ml Ro-07-
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estimate from the dog experiments was
judged to be the more useful figure because
it was derived from data obtained using
drug doses in the relevant range and in a
large mammal. If this estimate of 6 g
is correct, some advantage over metro-
nidazole could be expected.
After reviewing the toxicological data
available (Scharer, 1972), we felt it was
safe to proceed with certain single doses
in healthy volunteers as a necessary first
step in determining the dosage required
to produce serum concentrations of Ro-07-
0582 of I00 ,ig/ml. It could then be
decided whether further extensive investi-
gations into the radiosensitizing, pharma-
cological and toxicological properties of
Ro-07-0582 using regimens with multiple
large doses of the drug would be worth
while.
MATERIALS AND METHODS
Ro-07-0582 was supplied by Roche Pro-
ducts Ltd as 500 mg tablets. Six healthy
male scientists concerned with this research
project volunteered for the study. Subjects
received single doses of Ro-07-0582 as indi-
cated in the Table. A standard light break-
fast was eaten by all subjects before 08.00
hours on the morning of the study. Blood
was taken from the arm through an indwelling
intravenous catheter or by a series of vene-
punctures. A specimen was withdrawn just
before the drug was taken orally at 10.00
hours. Further specimens were taken fre-
quently for 3 h then hourly until 18.00 hours
then at 22.00 hours and also at 10.00 hours
and 18.00 hours on the next day. Coffee
was allowed 2 h after ingestion of the drug
and after this time meals and beverages
were not restricted. Ambulatory activity
was not restricted after the drug had been
taken. Subjects were asked to record all
details of any unusual symptoms and were
under constant medical supervision during
the first 12-h period after taking the drug.
The concentration of Ro-07-0582 in the
serum was determined directly as described
previously for metronidazole (Deutsch et al.,
1975) using a polarographic technique (Kane,
1961).
RESULTS
The curves of serum concentration
versus time obtained for each subject
are shown in Fig. 1. The serum half-life
of Ro-07-0582 of subjects varied from
9-8 to 17-5 h as shown in the Table. The
serum concentration of Ro-07-0582 at 4 h
is plotted against the dose administered
TIME h
Fio. I.-The serum concentration of Ro-07-0582 after single doses of 1-4 g. A I g Dosage (2 out of
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TABLE I.-Ro-07-0582 Serum Half-life after doses of 1-4 g ofRo-07-0582
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6
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37
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31
37
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37
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Wt (kg)
70
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76-5
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70
54.5
96-5
79.5
Dose (mg/kg)
14-3
10-4
13-0
13.0
28-6
36-7
41-5
50-3
Half-life (h)
9-8
12-8
11-0
10-7
10-3
11-9
12-5
17-5
12-100+2
0
DOSAGE Ro-07-0582 (mg/kg)
FIG. 2.-The serum concentration of Ro-07-0582 4 h after dosing as a function ofdosage expressed in
mg/kg body weight.
(expressed as mg/kg body weight) and
shown in Fig. 2.
No side-effects due to the drug were
reported by subjects after the 1 g dose.
However, after taking 2 g doses both
subjectsreportedmildinsomniathefollow-
ing night. In the 4 g subjects this symp-
tom was more marked and accompanied
bymildgastrointestinal disturbance. Only
transient feelings of nausea were experi-
enced after the 2 and 4 g doses and the
taste of the drug was not found to be
unpleasant. There was no obvious inter-
action with moderate quantities ofalcohol
taken with a meal 10 h after taking the
drug.
DISCUSSION
The method used for the measurement
of Ro-07-0582 in the serum specimens
48
is not specific. Metabolites in which the
2-nitroimidazole moiety remains intact
cannot be distinguished from the parent
compound in the presence ofserum. How-
ever, the values we have obtained have
been expressed assuming that all the
measured drug is Ro-07-0582. Attempts
to detect such metabolites using thin layer
and gas liquid chromatographic tech-
niques failed to do so, so that serum
concentrationshavebeenexpressedaccord-
ingly as jig Ro-07-0582/ml (Foster and
Flockhart, unpublished).
The rapid appearance of peak values
in Fig. 1 show that the drug was quickly
absorbed from the upper gastrointestinal
tract, probably including the stomach.
In 2 subjects some delay in reaching the
peak concentration was noted, which may
have been due to some delay in the
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stomach emptying as high serum concen-
trations were eventually achieved. It
would appear that the period 2-4 h after
administration would be the best time for
concomitant radiotherapy to be given as
the drug concentration is close to the
maximum achieved in all subjects at this
time and allows time for the drug to
diffuse to hypoxic cills of the tumour.
It appears from the limited data in
the Table that the serum half-life is
independent of the dose of drug over the
range 1-4 g, in spite of the fact that the
2 longest half-lives are for subjects
receiving the two 4 g doses, which may
have been an individual characteristic.
The subjects who took the 1 g dose,
followed a fortnight later by a 2 g or 4 g
dose hadnearlyidenticalhalf-lives. How-
ever, data from more subjects are required
to confirm this independence.
The data expressed in Fig. 2 are
consistent with a linear relationship
between the drug serum concentration
at 4 h and the dose administered expressed
in mg/kg. Extrapolation of the curve
(fitted by eye) by a factor of only 1 6
gives an average value of 78 mg/kg
required orally to achieve a serum concen-
tration of 100 ,ug/ml at 4 h. Direct calcu-
lation on a weight for weight basis from
individual points gives values ranging
from 70 to 100 mg/kg (5-7 g for a 70 kg
man). This is in close agreement with
the figure suggested by the dog experi-
ments mentioned above, and agrees with
the most optimistic prediction from the
data for low doses in man. Radio-
sensitization studies indicate that
increased benefit would be obtained if a
serum concentration of 200/tg/ml could
be achieved and tolerated (Denekamp,
Michael and Harris, 1974). From this
study it is estimated that doses of 10-14 g
would produce these levels if the serum
concentration continues to vary linearly
with amount administered.
Whilst tolerance to these high, albeit
single, doses was good in healthy male
subjects, the administration of larger
single doses to man would have to be
approached with caution. We conclude
that further studies ofthe radiosensitizing
properties of this drug in animal tumour
systems are warranted, particularly in
conjunction with fractionated radio-
therapy, and that investigations into the
toxicological and pharmacological proper-
ties of the drug should be continued.
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